Voluntary nationwide recall: Vancomycin (Amneal - March)
Apr. 2024Pharmacy Updates
Amneal Pharmaceuticals, LLC is recalling four lots of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5 mL. Vancomycin is used for treatment of certain bacterial infections.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Amneal at 1-833-582-0812. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
HPV Vaccination Resources
To help protect against cancers later in life, it is important to increase HPV vaccination rates in adolescents starting at age 9. According to the Centers for Disease Control and Prevention, HPV vaccination is routinely recommended at age 11 or 12, but the vaccine can be given starting at age 9.1 The Pennsylvania Cancer Coalition cites the following potential benefits of initiating the HPV vaccine series at age 9:2Mar. 2025Important Notices
Special notice: Important policy changes
Effective May 1, 2025, the following policies will be retired and replaced with prior authorization policies. For more information, please visit upmchp.us/policiesandprocedures.Mar. 2025Important Notices
CME Webinar: Essential Best Practices for Newborn Care: Ensuring Healthy Beginnings Through Comprehensive Care
Please join us for a live, CME-accredited webinar on Wednesday, May 7, from noon to 1 p.m. that will provide an overview of newborn care.Feb. 2025Education/Webinars